Stifel analyst David Grossman reiterated a Buy rating and $320 price target on Veeva (VEEV) after the company said that Bristol Myers (BMY) committed to Veeva Vault CRM, marking yet another top-20 Pharma customer formally committing to the platform, joining the likes of Merck (MRK), Novo Nordisk (NVO), GSK (GSK), Bayer (BAYRY), and Astellas (ALPMY). The firm noted that the company also got a verbal commitment from Gilead Sciences (GILD). While Monday’s announcement is not incremental, the formal announcement is a reminder of Veeva’s progress in converting the IB to the new platform, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva says Bristol Myers commits to Veeva Vault CRM
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Veeva Systems: Strategic Positioning and Growth Potential Justify Buy Rating
- Veeva receives another Top 20 Vault CRM commitment, says Raymond James
- Veeva says Gilead commits to Veeva Vault CRM